Aspire BioPharma, Inc. (ASBP) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aspire BioPharma, Inc. stock (ASBP) is currently trading at $0.80. Aspire BioPharma, Inc. PS ratio (Price-to-Sales) is 1858.75. WallStSmart rates ASBP as Sell.
- ASBP PE ratio analysis and historical PE chart
- ASBP PS ratio (Price-to-Sales) history and trend
- ASBP intrinsic value — DCF, Graham Number, EPV models
- ASBP stock price prediction 2025 2026 2027 2028 2029 2030
- ASBP fair value vs current price
- ASBP insider transactions and insider buying
- Is ASBP undervalued or overvalued?
- Aspire BioPharma, Inc. financial analysis — revenue, earnings, cash flow
- ASBP Piotroski F-Score and Altman Z-Score
- ASBP analyst price target and Smart Rating
Aspire BioPharma, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Aspire BioPharma, Inc. (ASBP) · 4 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Concerns around market cap and operating margin. Significant fundamental concerns warrant caution or avoidance.
Aspire BioPharma, Inc. (ASBP) Key Strengths (0)
Aspire BioPharma, Inc. (ASBP) Areas to Watch (4)
Losing money on operations
Very expensive at 1858.8x annual revenue
Very low institutional interest at 8.75%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Aspire BioPharma, Inc. (ASBP) Detailed Analysis Report
Overall Assessment
This company scores 6/100 in our Smart Analysis, earning a F grade. Out of 4 metrics analyzed, 0 register as strengths (avg 0/10) while 4 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
Limited fundamental strengths were identified. The bull case requires improvement in core metrics.
The Bear Case
The primary concerns are Operating Margin, Price/Sales, Institutional Own.. Some valuation metrics including Price/Sales (1858.75) suggest expensive pricing. Profitability pressure is visible in Operating Margin at -59016.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Operating Margin improves, as this is the primary drag on the overall score. Second, margin trajectory, with Operating Margin at -59016.00% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Operating Margin and Price/Sales are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ASBP Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ASBP's Price-to-Sales ratio of 1858.75x trades 33% below its historical average of 2784.07x (0th percentile). The current valuation is 50% below its historical high of 3753.22x set in Mar 2026, and 0% above its historical low of 1858.75x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~3753.2x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Aspire BioPharma, Inc. (ASBP) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Aspire BioPharma, Inc. operates as a stable business with moderate growth and solid fundamentals. Revenue reached 1,941 with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 10711% of revenue (207,899) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -1M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Aspire BioPharma, Inc..
Bottom Line
Aspire BioPharma, Inc. offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Aspire BioPharma, Inc.(ASBP)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Aspire Biopharma Holdings, Inc., early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company is headquartered in Humacao, Puerto Rico.